Table 3.
The demographic data of patients with different course of atopic dermatitis.
| Silent to mild AD (n = 39) | Moderate to severe AD (n = 61) | P | |
|---|---|---|---|
| Sex | |||
| Male | 21 (53.8%) | 22 (36.1%) | 0.080 |
| Female | 18 (46.2%) | 39 (63.9%) | |
| Age (years) Mean ± SD | 53.51 ± 17.98 | 40.95 ± 14.28 | <0.001 |
| Marital status | |||
| Single | 8 (20.5%) | 22 (36.1%) | 0.098 |
| Married | 31 (79.5%) | 39 (63.9%) | |
| Educational level | |||
| Diploma or lower | 13 (33.3%) | 11 (18%5) | 0.197 |
| B.Sc./B.A. | 19 (48.7%) | 34 (55.7%) | |
| MSc, MD, Ph.D. or higher | 7 (17.9%) | 16 (26.2%) | |
| History of alcohol consumption | |||
| Yes | 0 (0%) | 4 (6.6%) | 0.103 |
| No | 39 (100%) | 57 (93.4%) | |
| History of smoking | |||
| Yes | 5 (12.8%) | 2 (3.3%) | 0.068 |
| No | 34 (87.2%) | 59 (96.7%) | |
| Familial history of eczema | |||
| Yes | 9 (23.1%) | 27 (44.3%) | 0.031 |
| No | 30 (76.9%) | 34 (55.7%) | |
| AD exacerbation | |||
| Yes | 11 (28.2%) | 49 (80.3%) | <0.001 |
| No | 28 (71.8%) | 12 (19.7%) | |
| Chronic comorbiditiesa | |||
| Yes | 18 (46.2%) | 42 (68.9%) | 0.024 |
| No | 21 (53.8%) | 19 (31.1%) | |
| History of food/drug allergy | |||
| Yes | 19 (48.7%) | 44 (72.1%) | 0.018 |
| No | 20 (51.3%) | 17 (27.9%) | |
| Topical treatment | |||
| Topical steroids | 5 (12.8%) | 2 (3.3%) | 0.050 |
| Eucerin/vaseline | 4 (10.3%) | 1 (1.6%) | |
| More than 1 topicalb including steroids | 28 (71.8%) | 52 (85.2%) | |
| More than 1 topical without steroids | 2 (5.1%) | 6 (9.8%) | |
| Phototherapy | |||
| Yes | 13 (33.3%) | 31 (50.8%) | 0.086 |
| No | 26 (66.7%) | 30 (49.2%) | |
| Systemic treatment | |||
| No immunosuppressive medicationc | 28 (71.8%) | 31 (50.8%) | 0.038 |
| Immunosuppressive medication | 11 (28.2%) | 30 (49.2%) | |
| Phototherapy discontinuation | |||
| Yes | 31 (79.5%) | 53 (86.9%) | 0.325 |
| No | 8 (20.5%) | 8 (13.1%) | |
| Treatment discontinuation | |||
| Yes | 5 (12.8%) | 16 (26.2%) | 0.108 |
| No | 34 (87.2%) | 45 (73.8%) | |
| Treatment dose alteration | |||
| Yes, increased | 4 (10.3%) | 8 (13.1%) | 0.014 |
| Yes, decreased | 3 (7.7%) | 19 (31.1%) | |
| No | 32 (82.1%) | 34 (55.7%) | |
| Moisturizing usage | |||
| Yes | 17 (43.6%) | 52 (85.2%) | <0.001 |
| No | 22 (56.4%) | 9 (14.8%) | |
| The disease duration (years) Mean ± SD | 7.87 ± 6.55 | 12.06 ± 8.54 | 0.010 |
| Self-quarantine | |||
| No | 7 (17.9%) | 3 (4.9%) | 0.001 |
| Most times | 26 (66.7%) | 28 (45.9%) | |
| Always | 6 (15.4%) | 30 (49.2%) | |
| Handwashing | |||
| No | 5 (12.8%) | 2 (3.3%) | 0.004 |
| Most times | 21 (53.8%) | 19 (31.1%) | |
| Always | 13 (33.3%) | 40 (65.6%) | |
| Hand disinfection | |||
| Yes | 19 (48.7%) | 47 (77%) | 0.004 |
| No | 20 (51.3%) | 14 (23%) | |
| Surface disinfection | |||
| Yes | 31 (79.5%) | 55 (90.2%) | 0.133 |
| No | 8 (20.5%) | 6 (9.8%) | |
| History of COVID-19 infection | |||
| Yes | 1 (2.6%) | 2 (3.3%) | 0.838 |
| No | 38 (97.4%) | 59 (96.7%) | |
| Total anxiety | |||
| Mild | 38 (97.4%) | 49 (80.3%) | 0.013 |
| Moderate | 1 (2.6%) | 12 (19.7%) | |
| Severe | 0 | 0 | |
| The Corona disease anxiety scale Mean ± SD | 9.87 ± 6.76 | 7.52 ± 5.61 | 0.107 |
Abbreviations: atopic dermatitis, AD; Bachelor of Arts, B.A.; Bachelor of Science, B.Sc.; Coronavirus disease 2019, COVID-19; Master of Science, MSc; medical doctor, MD; number, n; doctoral degree, Ph.D.
a
Chronic comorbidities: cardiovascular diseases, diabetes mellitus, hypertension, hyperlipidemia, pulmonary diseases, thyroid disease, cancer, and others.
b
More than 1 topical: Eucerin/vaseline, calcineurin inhibitors.
c
Immunosuppressive medications: azathioprine, cyclosporine, methotrexate, prednisolone, more than one immunosuppressive medication, others.